Additional file 3 of Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts

Supplementary Material 3: Additional File 3: Table S1. Differentially expressed genes at baseline in gemcitabine-sensitive vs. gemcitabine-resistant models with unadjusted p < 0.001. Table S2. Significant differences in drug-associated changes in gene expression (i.e., deltas post-treatment vs. baseline) between sensitive and resistant models. Table S3. Significantly enriched gene sets between gemcitabine sensitive and resistant PDAC models at baseline. Table S4. Significantly enriched gene sets for genes with different drug-induced expression profiles between gemcitabine sensitive and resistant PDAC models. Table S5. Genes from MSigDB’s cancer hallmark gene sets with drug-induced expression changes significantly correlated with TGI%. Table S6. Significantly enriched pathways in 96 metabolic pathway gene sets. Table S7. Genes in glycolysis and OXPHOS pathways for which gemcitabine-induced expression changes were significantly correlated with TGI%. Table S8. Prevalence of TP53 mutational categories stratified by gemcitabine response status in the Yang and Novartis datasets. Fisher’s exact text p values are indicated for each dataset. Table S9. Significance of the effect of TP53 pathogenic status effect and differences in expression or expression changes on TGI% at 21 days for p53 target genes adjusted for TP53 effect or gene effect.